• 1
    Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 9971008
  • 2
    Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998; 160: 166871
  • 3
    Witjes JA, Meijden AP, Collette L et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998; 52: 40310
  • 4
    Sylvester RJ, Brausi MA, Kirkels WJ et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: 76673
  • 5
    Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 9921001
  • 6
    Pansadoro V, Emiliozzi P, de Paula F et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 22731
  • 7
    Hurle R, Losa A, Manzetti A, Lembo A. Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 25863
  • 8
    Tanaka N, Kikuchi E, Matsumoto K et al. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer. J Urol 2011; 185: 4505
  • 9
    Klein EA, Rogatko A, Herr HW. Management of local bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol 1992; 147: 6015
  • 10
    Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 65861
  • 11
    Sarosdy MF, Manyak MJ, Sagalowsky AI et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology 1998; 51: 22631
  • 12
    Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24: 272934
  • 13
    Herr HW, Dalbagni G. Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 2003; 169: 17068
  • 14
    Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66: 10825
  • 15
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009; 27: 1559
  • 16
    Herr HW, Badalament RA, Amato DA et al. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 229
  • 17
    Andius P, Holmäng S. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004; 93: 9804